Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01699178 · ClinicalTrials.gov registry record · Phase 3
Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men
A Phase 3 study, sponsored by Clarus Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 182
- Enrollment target
NCT01699178 is a Phase 3 study that has completed, run by Clarus Therapeutics. The registered enrollment target is 182 participants.
The verdict
NCT01699178, a Phase 3 study, has completed, sponsored by Clarus Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 182 participants
- Enrollment target
Study Summary
The purpose of this one year extension (follow-up) study is to gather additional safety data in hypogonadal men treated with oral TU or AndroGel who have completed the 12-month Phase III study CLAR-09007.
Interventions
- DRUG Oral testosterone undecanoate
- DRUG Transdermal testosterone gel (AndroGel)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2012-08 |
| Est. Completion | 2014-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01699178
The ClinicalTrials.gov registry entry for NCT01699178 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 182 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clarus Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oral testosterone undecanoate is the first listed.
NCT01699178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01699178 about?
NCT01699178 is a clinical study titled "Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men". The purpose of this one year extension (follow-up) study is to gather additional safety data in hypogonadal men treated with oral TU or AndroGel who have completed the 12-month Phase III study CLAR-09007.
What is the current status of trial NCT01699178?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 182 participants. The study started on 2012-08. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01699178?
The interventions under investigation include: Oral testosterone undecanoate (DRUG), Transdermal testosterone gel (AndroGel) (DRUG).
Who is sponsoring clinical trial NCT01699178?
This trial is sponsored by Clarus Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.